Literature DB >> 25260236

Epilepsy: new advances.

Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3, Torbjörn Tomson4.   

Abstract

Epilepsy affects 65 million people worldwide and entails a major burden in seizure-related disability, mortality, comorbidities, stigma, and costs. In the past decade, important advances have been made in the understanding of the pathophysiological mechanisms of the disease and factors affecting its prognosis. These advances have translated into new conceptual and operational definitions of epilepsy in addition to revised criteria and terminology for its diagnosis and classification. Although the number of available antiepileptic drugs has increased substantially during the past 20 years, about a third of patients remain resistant to medical treatment. Despite improved effectiveness of surgical procedures, with more than half of operated patients achieving long-term freedom from seizures, epilepsy surgery is still done in a small subset of drug-resistant patients. The lives of most people with epilepsy continue to be adversely affected by gaps in knowledge, diagnosis, treatment, advocacy, education, legislation, and research. Concerted actions to address these challenges are urgently needed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25260236     DOI: 10.1016/S0140-6736(14)60456-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  191 in total

1.  Down-regulation of Long Noncoding RNA MALAT1 Protects Hippocampal Neurons Against Excessive Autophagy and Apoptosis via the PI3K/Akt Signaling Pathway in Rats with Epilepsy.

Authors:  Qiang Wu; Xuewei Yi
Journal:  J Mol Neurosci       Date:  2018-06-01       Impact factor: 3.444

2.  Valproic Acid versus Lamotrigine as First-line Monotherapy in Newly Diagnosed Idiopathic Generalized Tonic -Clonic Seizures in Adults - A Randomized Controlled Trial.

Authors:  Vishal Prakash Giri; Om Prakash Giri; Farhan Ahmad Khan; Narendra Kumar; Ajay Kumar; Ataul Haque
Journal:  J Clin Diagn Res       Date:  2016-07-01

3.  Inhibition of miR-203 Reduces Spontaneous Recurrent Seizures in Mice.

Authors:  Soon-Tae Lee; Daejong Jeon; Kon Chu; Keun-Hwa Jung; Jangsup Moon; Junsang Sunwoo; Dong-Kyu Park; Hyunwoo Yang; Ji-Hyun Park; Manho Kim; Jae-Kyu Roh; Sang Kun Lee
Journal:  Mol Neurobiol       Date:  2016-05-10       Impact factor: 5.590

Review 4.  Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.

Authors:  Matt Shirley; Sohita Dhillon
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 5.  Enabling biodegradable functional biomaterials for the management of neurological disorders.

Authors:  Dingying Shan; Chuying Ma; Jian Yang
Journal:  Adv Drug Deliv Rev       Date:  2019-06-20       Impact factor: 15.470

6.  Microglial depletion aggravates the severity of acute and chronic seizures in mice.

Authors:  Wenning Wu; Yujiao Li; Yujia Wei; Dale B Bosco; Manling Xie; Ming-Gao Zhao; Jason R Richardson; Long-Jun Wu
Journal:  Brain Behav Immun       Date:  2020-07-02       Impact factor: 7.217

Review 7.  The role of exosomal microRNAs in central nervous system diseases.

Authors:  Yifei Yu; Kun Hou; Tong Ji; Xishu Wang; Yining Liu; Yangyang Zheng; Jinying Xu; Yi Hou; Guangfan Chi
Journal:  Mol Cell Biochem       Date:  2021-01-29       Impact factor: 3.396

Review 8.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 9.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

Review 10.  Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents.

Authors:  Xiaohuan Xia; Yi Wang; Yunlong Huang; Han Zhang; Hongfang Lu; Jialin C Zheng
Journal:  Prog Neurobiol       Date:  2019-09-19       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.